IP Library Granted Patent US 8,183,209
Granted Patent B2
US 8,183,209 · App. 13/247,782 · Granted May 22, 2012

Treatment of T-cell mediated diseases

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,183,209
App. No.
13/247,782
Granted
May 22, 2012
Kind
B2
Abstract

The invention provides a method of treating T-cell mediated diseases and a method of inhibiting the activation of T-cells using certain diketopiperazines. The invention also provides methods of synthesizing diketopiperazines and pharmaceutical compositions comprising certain diketopiperazines. The invention further provides methods of making improved pharmaceutical compositions of proteins and peptides by either increasing or decreasing the content of diketopiperazines in the compositions and the resultant improved pharmaceutical compositions.

Claims (12)

1. A pharmaceutical composition comprising a filtrate of a solution of a protein or peptide, wherein the filtrate is produced by passing the solution of a protein or peptide over an ultrafiltration membrane with a molecular weight cutoff that retains a protein selected from the group consisting of albumin, immunoglobulin and erythropoietin, and wherein the filtrate comprises: a diketopiperazine selected from the group consisting of YE-DKP, MR-DKP and DA-DKP.

2. The composition of claim 1 wherein the filtrate contains components having molecular weights less than 3000.

3. The composition of claim 1 wherein the protein or peptide is a human protein or peptide.

4. The composition of claim 1 wherein the protein or peptide is a human albumin.

5. The composition of claim 2 wherein the protein or peptide is a human protein or peptide.

6. The composition of claim 2 wherein the protein or peptide is a human albumin.

7. A filtrate of a solution of a protein or peptide, wherein the filtrate is produced by passing the solution of a protein or peptide over an ultrafiltration membrane with a molecular weight cutoff that retains a protein selected from the group consisting of albumin, immunoglobulin and erythropoietin, and wherein the filtrate comprises a diketopiperazine selected from the group consisting of YE-DKP, MR-DKP and DA-DKP.

8. The filtrate of claim 7 wherein the filtrate contains components having molecular weights less than 3000.

9. The filtrate of claim 7 wherein the protein or peptide is a human protein or peptide.

10. The filtrate of claim 7 wherein the protein or peptide is a human albumin.

11. The filtrate of claim 8 wherein the protein or peptide is a human protein or peptide.

12. The filtrate of claim 8 wherein the protein or peptide is a human albumin.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 9, 2013
From: DMI ACQUISITION CORP.
To: AMPIO PHARMACEUTICALS, INC.
Reel/Frame 031305/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 4, 2013
From: DMI BIOSCIENCES, INC.
To: DMI ACQUISITION CORP.
Reel/Frame 029565/0273 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 28, 2012
From: BAR-OR, DAVID; BAR-OR, RAPHAEL; SHIMONKEVITZ, RICHARD
To: DMI BIOSCIENCES, INC.
Reel/Frame 029543/0645 →